Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Grupo Fleury beats revenue estimates, slightly misses EPS in Q1 2026

Grupo Fleury reported Q1 2026 revenue of USD 2.22 billion (+10.1% YoY), exceeding expectations, while earnings per share of USD 0.35 narrowly missed the USD 0.354 estimate by 1.13%. Growth was driven mainly by the B2C segment; gross profit and EBITDA also rose by double digits. The stock fell 1.49% after hours; management emphasizes further investment in innovation and expansion while monitoring macroeconomic and regulatory risks. » More on de.investing.com
Grupo Fleury reports double-digit revenue growth in Q1 2026 on 100th anniversary

Grupo Fleury posted revenue of R$2.4 billion in Q1 2026 (+10.1%), beating market expectations, while earnings per share of $0.35 slightly missed the $0.354 estimate. EBITDA rose to R$606.0 million (+10.7%) and net income to R$201.2 million (+12.2%), accompanied by a ROIC of 17% and a conservative leverage of 1.0x net debt/EBITDA. Management highlights successful diversification into an integrated health ecosystem, launched the Life‑Care offering, and expects further growth despite challenges in the B2B segment. » More on de.investing.com
Fleury reports double-digit revenue growth in Q4 2025 in its hundredth year

Grupo Fleury posted revenue growth of 12.2% in Q4 2025 to R$2.238bn and R$9.003bn for the full year (+8.2%). EBITDA rose 12.5% in the quarter to R$455.9m with a stable margin of 22.1%, and operating cash conversion was 99.9%; annual net income was R$612.8m. The company saw strong growth in the B2C segment and in New Links, maintains conservative leverage of 1.0x (net debt/EBITDA) and shows a high dividend yield of 10.65%. Despite results beating expectations, the stock fell after hours, reflecting profit-taking after last year’s strong run and uncertainty about sustainable growth rates. » More on de.investing.com
Grupo Fleury surpasses expectations in Q4 2025, stock falls after-hours

Grupo Fleury reported Q4 2025 revenue of USD 2.06 billion and EPS of USD 0.138, both slightly above analysts' estimates. Despite strong results, the share price fell 3.38% in after-hours trading to USD 16.02. Operating cash flow and EBITDA margins remained robust; the outlook is stable with moderate EPS growth for 2026–2027. Risks include market saturation, economic pressure in Brazil, and currency fluctuations. » More on de.investing.com
Grupo Fleury: quarterly profit beats expectations, shares dip slightly

Grupo Fleury reported Q4 2025 EPS of $0.138 (forecast $0.1339) and revenue of $2.06 billion, both above expectations. Despite growth in B2C and B2B, a stable EBITDA margin (22.1%) and a 14.7% rise in net income, the stock fell 0.87% in after-hours trading to $16.03. The company reported margin pressure from high-priced drug applications, announced cost-optimization programs and gave an EPS forecast of $0.06 for Q1/Q2 2026 while continuing to focus on expanding its diagnostics portfolio. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Fleury SA has already paid €0.0556 in dividends. The last payout was in September.

Financials

In the last quarter, Fleury SA had revenue of €392.16M and net profit of €37.55M

(EUR)	June 2026	YoY
Revenue	392.16M	24.01%
Gross profit	100.32M	21.65%
Net profit	37.55M	57.86%
EBITDA	103.51M	13.24%

Fundamentals

Metric	Value
Market capitalization	€1.82B
Number of shares	543.63M
52-week high/low	€4.62 - €2.24
Dividend yield	5.68%
Dividends TTM	€0.19
Beta	0.21
P/E ratio	15.96
PEG ratio	0.93
P/B ratio	2.08
P/S ratio	1.28

Company profile

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.